Send your question to our coding/reimbursement experts Ray Painter, MD, and Mark Painter.
Have a question about coding or reimbursement? Send your question to our coding/reimbursement experts Ray Painter, MD, and Mark Painter c/o Urology Times. To submit your question, use the "Post a Comment" form below.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.